Pulse Biosciences, Inc. (PLSE)

NASDAQ • Healthcare

$53.02

+$0.34 (+0.6%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$52.44

Previous Close$53.02

Day Range$51.47 - $55

Avg. Volume (3M)420.8K

Market Cap$3.7B

52 Week Range

$12.56$58.9

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$434K100%

Gross Profitminus cost of goods$161K37%

Fundamentals & Financials

Revenue (TTM)

$1.1M

Net Income (TTM)

-$80M

EPS (TTM)

-$1.17

ROA (TTM)

-69.27%

Current Ratio

9.63

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-7.7%Q3 2025-$0.28

+6.5%Q4 2025-$0.29

+1.9%Q1 2026-$0.26

+15.6%Q2 2026-$0.27

-16.1%Q3 2026-$0.36

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -16.1%

Pulse Biosciences trailed consensus on both EPS and revenue in the second fiscal quarter of 2026, reported August 6, 2026, with EPS of -$0.36 trailing the -$0.31 estimate by -$0.05 and revenue of $434,000.00 trailing the $500,000.00 estimate (-13.2%). Net income came in at roughly -$24.7 million, down 29% from about -$19.2 million a year ago, and EPS was down 29% from -$0.28 a year ago. The quarter also posted an operating loss of about -$25.3 million, alongside revenue of about $0.4 million. For the next period, consensus calls for EPS of -$0.35 on revenue of $625,000.00.

Next report — what to expect

Pulse Biosciences, Inc. (PLSE) reports next on November 4, 2026. Wall Street is looking for consensus EPS of -$0.35 on revenue of $604,167.00. In recent results, PLSE has beaten EPS in 6 of 8 most recent quarters, so traders may focus on whether earnings land above or below that baseline.

View full earnings history

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. develops medical technology and trades on the NASDAQ under PLSE. In healthcare, it operates as a maker of medical instruments and supplies built around the CellFX System, and it fits the profile of a small-cap device company founded in 2014.

Name

Pulse Biosciences, Inc.

CEO

Paul Arthur LaViolette

Website

www.pulsebiosciences.com

Industry

Healthcare

Year Founded

2014

Employees

116

Today's Snapshot

AI-generated

The day ended with PLSE 0.7% higher at 53.02, outperforming a weaker sector. Earnings are due from PLSE on 4 November.

Trading Volume

Above 10d avg 399.9K

452K

vs S&P 500 Today

Outperforming Market

+1.17%

Updated: October 23, 2026 at 20:17 UTC

Technical Indicators

6 Buy1 Neutral1 Sell

PLSE at 53.02 carries a Buy bias as price is above short-, medium- and long-term moving averages and momentum signals are generally positive. RSI is in bullish territory, CCI shows notable strength, and MACD is positive, which together indicate upward momentum even though ADX suggests only moderate trend strength. Volume trends via OBV are supportive while ATR points to above-average volatility. The pivot at 52.12 is marginally below current price, offering nearby support as the stock trades near the upper Bollinger band. Technical takeaway: Buy — price sits above key averages with momentum and volume in support.

All signals

EMA (5 indicators)$33.00 - $50.35
Buy
RSI (14)57.54
Neutral
Stochastic %K (14, 3, 3)81.94
Sell
MACD Level (12, 26)0.29
Buy

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.